4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic product development, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021. The webcast will be accessible on their website starting at 8:00 a.m. ET (1:00 p.m. BST). 4D pharma specializes in drugs derived from the microbiome, utilizing their proprietary MicroRx® platform. The company has five clinical programs, including collaborations with MSD for vaccine-related LBPs. Further details can be found at www.4dpharmaplc.com.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021.

A webcast of the presentation will be available on the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com beginning Tuesday, October 19, 2021 at 8:00 a.m. ET (1:00 p.m. BST).

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005054/en/

4D pharma

Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

Source: 4D pharma

FAQ

When will 4D pharma present at the Jefferies Virtual Next Generation IBD Therapeutics Summit?

4D pharma will present on October 19, 2021.

What time will the presentation by 4D pharma start?

The presentation will start at 8:00 a.m. ET (1:00 p.m. BST).

Where can I watch the 4D pharma presentation?

The presentation can be watched on the 'Events' section of 4D pharma's website at www.4dpharmaplc.com.

What is the focus of 4D pharma's clinical programs?

4D pharma's clinical programs focus on Live Biotherapeutics, including treatments for solid tumors, asthma, and Irritable Bowel Syndrome.

What is the stock symbol for 4D pharma?

The stock symbol for 4D pharma is LBPS.